Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness
Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kumar, Swarup [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature - Wölter, M. ELSEVIER, 2016transfer abstract, Oxford [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:20 ; year:2018 ; number:2 ; pages:75-81 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.tgie.2018.02.002 |
|---|
| Katalog-ID: |
ELV043547567 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV043547567 | ||
| 003 | DE-627 | ||
| 005 | 20230626003815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tgie.2018.02.002 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000268A.pica |
| 035 | |a (DE-627)ELV043547567 | ||
| 035 | |a (ELSEVIER)S1096-2883(18)30012-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |q VZ |
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 510 |a 004 |q VZ |
| 084 | |a 31.80 |2 bkl | ||
| 084 | |a 54.80 |2 bkl | ||
| 100 | 1 | |a Kumar, Swarup |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. | ||
| 520 | |a Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. | ||
| 650 | 7 | |a Adverse outcomes |2 Elsevier | |
| 650 | 7 | |a Barrett’s esophagus |2 Elsevier | |
| 650 | 7 | |a Endoscopic therapy |2 Elsevier | |
| 650 | 7 | |a Patient values |2 Elsevier | |
| 650 | 7 | |a Cost-effectiveness |2 Elsevier | |
| 700 | 1 | |a Iyer, Prasad G. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Wölter, M. ELSEVIER |t Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature |d 2016transfer abstract |g Oxford [u.a.] |w (DE-627)ELV024470511 |
| 773 | 1 | 8 | |g volume:20 |g year:2018 |g number:2 |g pages:75-81 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.tgie.2018.02.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 912 | |a GBV_ILN_72 | ||
| 936 | b | k | |a 31.80 |j Angewandte Mathematik |q VZ |
| 936 | b | k | |a 54.80 |j Angewandte Informatik |q VZ |
| 951 | |a AR | ||
| 952 | |d 20 |j 2018 |e 2 |h 75-81 |g 7 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
s k sk |
|---|---|
| matchkey_str |
kumarswarupiyerprasadg:2018----:nocpcrdctoteayobreteohgsdesotoepteta |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
31.80 54.80 |
| publishDate |
2018 |
| allfields |
10.1016/j.tgie.2018.02.002 doi GBV00000000000268A.pica (DE-627)ELV043547567 (ELSEVIER)S1096-2883(18)30012-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 510 004 VZ 31.80 bkl 54.80 bkl Kumar, Swarup verfasserin aut Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness 2018transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. Adverse outcomes Elsevier Barrett’s esophagus Elsevier Endoscopic therapy Elsevier Patient values Elsevier Cost-effectiveness Elsevier Iyer, Prasad G. oth Enthalten in Elsevier Wölter, M. ELSEVIER Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature 2016transfer abstract Oxford [u.a.] (DE-627)ELV024470511 volume:20 year:2018 number:2 pages:75-81 extent:7 https://doi.org/10.1016/j.tgie.2018.02.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT GBV_ILN_72 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ AR 20 2018 2 75-81 7 045F 610 |
| spelling |
10.1016/j.tgie.2018.02.002 doi GBV00000000000268A.pica (DE-627)ELV043547567 (ELSEVIER)S1096-2883(18)30012-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 510 004 VZ 31.80 bkl 54.80 bkl Kumar, Swarup verfasserin aut Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness 2018transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. Adverse outcomes Elsevier Barrett’s esophagus Elsevier Endoscopic therapy Elsevier Patient values Elsevier Cost-effectiveness Elsevier Iyer, Prasad G. oth Enthalten in Elsevier Wölter, M. ELSEVIER Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature 2016transfer abstract Oxford [u.a.] (DE-627)ELV024470511 volume:20 year:2018 number:2 pages:75-81 extent:7 https://doi.org/10.1016/j.tgie.2018.02.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT GBV_ILN_72 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ AR 20 2018 2 75-81 7 045F 610 |
| allfields_unstemmed |
10.1016/j.tgie.2018.02.002 doi GBV00000000000268A.pica (DE-627)ELV043547567 (ELSEVIER)S1096-2883(18)30012-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 510 004 VZ 31.80 bkl 54.80 bkl Kumar, Swarup verfasserin aut Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness 2018transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. Adverse outcomes Elsevier Barrett’s esophagus Elsevier Endoscopic therapy Elsevier Patient values Elsevier Cost-effectiveness Elsevier Iyer, Prasad G. oth Enthalten in Elsevier Wölter, M. ELSEVIER Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature 2016transfer abstract Oxford [u.a.] (DE-627)ELV024470511 volume:20 year:2018 number:2 pages:75-81 extent:7 https://doi.org/10.1016/j.tgie.2018.02.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT GBV_ILN_72 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ AR 20 2018 2 75-81 7 045F 610 |
| allfieldsGer |
10.1016/j.tgie.2018.02.002 doi GBV00000000000268A.pica (DE-627)ELV043547567 (ELSEVIER)S1096-2883(18)30012-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 510 004 VZ 31.80 bkl 54.80 bkl Kumar, Swarup verfasserin aut Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness 2018transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. Adverse outcomes Elsevier Barrett’s esophagus Elsevier Endoscopic therapy Elsevier Patient values Elsevier Cost-effectiveness Elsevier Iyer, Prasad G. oth Enthalten in Elsevier Wölter, M. ELSEVIER Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature 2016transfer abstract Oxford [u.a.] (DE-627)ELV024470511 volume:20 year:2018 number:2 pages:75-81 extent:7 https://doi.org/10.1016/j.tgie.2018.02.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT GBV_ILN_72 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ AR 20 2018 2 75-81 7 045F 610 |
| allfieldsSound |
10.1016/j.tgie.2018.02.002 doi GBV00000000000268A.pica (DE-627)ELV043547567 (ELSEVIER)S1096-2883(18)30012-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 510 004 VZ 31.80 bkl 54.80 bkl Kumar, Swarup verfasserin aut Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness 2018transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. Adverse outcomes Elsevier Barrett’s esophagus Elsevier Endoscopic therapy Elsevier Patient values Elsevier Cost-effectiveness Elsevier Iyer, Prasad G. oth Enthalten in Elsevier Wölter, M. ELSEVIER Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature 2016transfer abstract Oxford [u.a.] (DE-627)ELV024470511 volume:20 year:2018 number:2 pages:75-81 extent:7 https://doi.org/10.1016/j.tgie.2018.02.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT GBV_ILN_72 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ AR 20 2018 2 75-81 7 045F 610 |
| language |
English |
| source |
Enthalten in Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature Oxford [u.a.] volume:20 year:2018 number:2 pages:75-81 extent:7 |
| sourceStr |
Enthalten in Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature Oxford [u.a.] volume:20 year:2018 number:2 pages:75-81 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Angewandte Mathematik Angewandte Informatik |
| institution |
findex.gbv.de |
| topic_facet |
Adverse outcomes Barrett’s esophagus Endoscopic therapy Patient values Cost-effectiveness |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature |
| authorswithroles_txt_mv |
Kumar, Swarup @@aut@@ Iyer, Prasad G. @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV024470511 |
| dewey-sort |
3610 |
| id |
ELV043547567 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV043547567</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626003815.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.tgie.2018.02.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000268A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV043547567</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1096-2883(18)30012-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">510</subfield><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kumar, Swarup</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adverse outcomes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Barrett’s esophagus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Endoscopic therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Patient values</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cost-effectiveness</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Iyer, Prasad G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Wölter, M. ELSEVIER</subfield><subfield code="t">Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature</subfield><subfield code="d">2016transfer abstract</subfield><subfield code="g">Oxford [u.a.]</subfield><subfield code="w">(DE-627)ELV024470511</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:75-81</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.tgie.2018.02.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2018</subfield><subfield code="e">2</subfield><subfield code="h">75-81</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Kumar, Swarup |
| spellingShingle |
Kumar, Swarup ddc 610 ddc 570 ddc 540 ddc 510 bkl 31.80 bkl 54.80 Elsevier Adverse outcomes Elsevier Barrett’s esophagus Elsevier Endoscopic therapy Elsevier Patient values Elsevier Cost-effectiveness Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness |
| authorStr |
Kumar, Swarup |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV024470511 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences 510 - Mathematics 004 - Data processing & computer science |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 570 VZ 540 VZ 510 004 VZ 31.80 bkl 54.80 bkl Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness Adverse outcomes Elsevier Barrett’s esophagus Elsevier Endoscopic therapy Elsevier Patient values Elsevier Cost-effectiveness Elsevier |
| topic |
ddc 610 ddc 570 ddc 540 ddc 510 bkl 31.80 bkl 54.80 Elsevier Adverse outcomes Elsevier Barrett’s esophagus Elsevier Endoscopic therapy Elsevier Patient values Elsevier Cost-effectiveness |
| topic_unstemmed |
ddc 610 ddc 570 ddc 540 ddc 510 bkl 31.80 bkl 54.80 Elsevier Adverse outcomes Elsevier Barrett’s esophagus Elsevier Endoscopic therapy Elsevier Patient values Elsevier Cost-effectiveness |
| topic_browse |
ddc 610 ddc 570 ddc 540 ddc 510 bkl 31.80 bkl 54.80 Elsevier Adverse outcomes Elsevier Barrett’s esophagus Elsevier Endoscopic therapy Elsevier Patient values Elsevier Cost-effectiveness |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
p g i pg pgi |
| hierarchy_parent_title |
Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature |
| hierarchy_parent_id |
ELV024470511 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry 510 - Mathematics 000 - Computer science, knowledge & systems |
| hierarchy_top_title |
Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV024470511 |
| title |
Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness |
| ctrlnum |
(DE-627)ELV043547567 (ELSEVIER)S1096-2883(18)30012-3 |
| title_full |
Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness |
| author_sort |
Kumar, Swarup |
| journal |
Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature |
| journalStr |
Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science 000 - Computer science, information & general works |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
75 |
| author_browse |
Kumar, Swarup |
| container_volume |
20 |
| physical |
7 |
| class |
610 610 DE-600 570 VZ 540 VZ 510 004 VZ 31.80 bkl 54.80 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kumar, Swarup |
| doi_str_mv |
10.1016/j.tgie.2018.02.002 |
| dewey-full |
610 570 540 510 004 |
| title_sort |
endoscopic eradication therapy for barrett’s esophagus: adverse outcomes, patient values, and cost-effectiveness |
| title_auth |
Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness |
| abstract |
Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. |
| abstractGer |
Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. |
| abstract_unstemmed |
Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT GBV_ILN_72 |
| container_issue |
2 |
| title_short |
Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness |
| url |
https://doi.org/10.1016/j.tgie.2018.02.002 |
| remote_bool |
true |
| author2 |
Iyer, Prasad G. |
| author2Str |
Iyer, Prasad G. |
| ppnlink |
ELV024470511 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.tgie.2018.02.002 |
| up_date |
2024-07-06T19:06:57.808Z |
| _version_ |
1803857761725841408 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV043547567</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626003815.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.tgie.2018.02.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000268A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV043547567</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1096-2883(18)30012-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">510</subfield><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kumar, Swarup</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Endoscopic therapy for Barrett’s esophagus (BE) aims to replace dysplastic BE epithelium with neosquamous epithelium to prevent and reduce the risk of progression to esophageal adenocarcinoma (EAC) and treat early-stage EAC. Various modalities of endotherapy of dysplastic BE are described. Although endoscopic therapy is safe and effective in treating subjects with intramucosal carcinoma (IMCa), high-grade dysplasia (HGD), and confirmed low-grade dysplasia (LGD), challenges to successful treatment are being recognized. Though adverse outcomes of endotherapy such as bleeding, perforation, pain, and stricture formation are observed, they are not common and can usually be treated medically or endoscopically. Patient values and preferences toward endoscopic therapy and the cost-effectiveness of these endoscopic approaches also have crucial implications for the selection of appropriate treatment and subsequent outcomes in patients with BE.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adverse outcomes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Barrett’s esophagus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Endoscopic therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Patient values</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cost-effectiveness</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Iyer, Prasad G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Wölter, M. ELSEVIER</subfield><subfield code="t">Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature</subfield><subfield code="d">2016transfer abstract</subfield><subfield code="g">Oxford [u.a.]</subfield><subfield code="w">(DE-627)ELV024470511</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:75-81</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.tgie.2018.02.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2018</subfield><subfield code="e">2</subfield><subfield code="h">75-81</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3986425 |